Literature DB >> 3904388

Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study.

H S Ribner, D A Plucinski, A M Hsieh, D Bresnahan, A Molteni, J Askenazi, M Lesch.   

Abstract

The effects of the digitalis glycosides on systemic vascular resistance (SVR) in patients with congestive heart failure (CHF) are controversial. Most investigators report a reduction in total SVR, an action that has been attributed primarily to withdrawal of elevated sympathetic tone. Direct proof of this hypothesis is lacking, however, and the roles played by the renin-angiotensin-aldosterone and vasopressin systems have not been fully explored. Moreover, in several studies of patients with CHF, SVR did not decrease after the administration of digitalis. To clarify these issues, the hemodynamic and hormonal effects of digoxin were correlated in 11 normotensive men in sinus rhythm with CHF due to dilated cardiomyopathy. Patients were evaluated at rest and during submaximal exercise before and 6 hours after the intravenous infusion of 1.0 mg of digoxin (mean serum concentration 1.7 ng/ml). With digoxin therapy, heart rate, pulmonary wedge pressure and right atrial pressure declined and cardiac output increased. Although vasopressin was unchanged, both plasma norepinephrine concentrations and plasma renin activity decreased, the reduction in norepinephrine correlating with the increase in cardiac output. Despite these hemodynamic and hormonal effects, there was no change in total SVR at rest or during exercise. It is concluded that the improvement in cardiac function with digoxin in this patient group was a result of the inotropic properties of the drug, without an associated reduction in impedance. The failure of total SVR to decrease despite decreases in plasma norepinephrine levels and plasma renin activity might be explained by concomitant digitalis-induced vasoconstriction, impaired ability of arterioles to dilate in CHF, or offsetting alterations in other vasoactive hormone systems.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3904388     DOI: 10.1016/0002-9149(85)90778-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Evolving therapeutic concepts and imaging in ischemic cardiomyopathy.

Authors:  A Lahiri; R Senior
Journal:  J Nucl Cardiol       Date:  1998 Nov-Dec       Impact factor: 5.952

Review 2.  To dig or not to dig.

Authors:  G R Dagenais; J M Brophy
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

3.  Role of mitochondrial dysfunction in cardiac glycoside toxicity.

Authors:  Ting Liu; David A Brown; Brian O'Rourke
Journal:  J Mol Cell Cardiol       Date:  2010-07-08       Impact factor: 5.000

Review 4.  Digoxin in the treatment of patients with chronic heart failure. Its place in therapy.

Authors:  B F Uretsky
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

Review 5.  Current guidelines for the treatment of congestive heart failure.

Authors:  F X Kleber; R Wensel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 6.  [Status of digitalis in therapy of acute and chronic heart failure].

Authors:  T A Fischer; N Treese
Journal:  Med Klin (Munich)       Date:  1997-09-15

Review 7.  Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors:  J Tauke; D Han; M Gheorghiade
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 8.  Contemporary Controversies in Digoxin Use in Systolic Heart Failure.

Authors:  Chonyang L Albert; Forum Kamdar; Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2016-10

9.  Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat, and digoxin.

Authors:  H N Sabbah; T B Levine; M Gheorghiade; T Kono; S Goldstein
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 10.  Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.

Authors:  Brent N Reed; Sarah E Street; Brian C Jensen
Journal:  Heart Fail Clin       Date:  2014-08-14       Impact factor: 3.179

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.